Pylarify injection OY3
Active Awarded Last action
- Contract number
- 36C24826N0189
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 8
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,248,835
Award facts
- Contract value 100% obligated
- $1,248,834.60 Current and potential, with all options
- Completion date 40% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 8, awarded a Blanket Purchase Agreement (BPA) call to Progenics Pharmaceuticals Inc. (a division of Lantheus Medical Imaging, Inc.) on January 1, 2026, for the supply of PYLARIFY Injection with a ceiling value of $1.25M and an ultimate completion date of December 31, 2027. This is a firm fixed-price contract with no set-aside designation issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The place of performance is North Billerica, Billerica, Massachusetts. PYLARIFY (piflufolastat F-18) is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans to detect and localize prostate cancer in patients, representing a critical radiopharmaceutical for the VA's medical imaging programs across its healthcare network.
This award is a child contract under a larger Blanket Purchase Agreement vehicle with Progenics Pharmaceuticals, which itself operates as part of the Lantheus Holdings portfolio of radiopharmaceutical suppliers. Progenics and its parent company maintain multiple significant Indefinite Delivery Vehicles with the VA and Defense Health Agency, with total potential values reaching into the hundreds of millions. These vehicles enable efficient ordering and delivery of specialized nuclear medicine and diagnostic imaging agents across VA medical centers and military treatment facilities nationwide, supporting comprehensive cancer detection and diagnostic imaging programs throughout the federal healthcare system.
Quick answers
Who was awarded contract 36C24826N0189?
36C24826N0189 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 8 (Veterans Health Administration) on January 1, 2026.
How much is contract 36C24826N0189 worth?
The government has obligated $1,248,835 on 36C24826N0189.
Is contract 36C24826N0189 an order under another contract?
Yes. 36C24826N0189 is a BPA call under 36F79719D0170-36C24823A0018, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24826N0189 competed?
The extent of competition for 36C24826N0189 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award